Trial Protocol ID USOR 20138_D361BC00001 *STAR*

Trial Description

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281)

Contact us regarding Clinical Trials at or call us at 877-664-7724

Disease Types


  • AstraZeneca NCT ID

  • NCT04493853